FindTrial
Sign In

To compare the efficacy and safety of oral dexamethasone and mycophenolate mofetil in the treatment of active vitiligo.

A Randomized prospective study comparing oral mini pulse dexamethasone and mycophenolate mofetil in the treatment of unstable vitiligo

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/011664
Enrollment
50
Registered
2018-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Actively progressive non-segmental vitiligo

Interventions

Intervention1: Mycophenolate mofetil: Mycophenolate mofetil shall be started in patients having active progressive vitiligo at 500 mg twice daily and shall be increased up to 1 gram twice daily. This

Sponsors

PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Active progressive non-segmental vitiligo

Exclusion criteria

Exclusion criteria: • Age • Leucoderma secondary to other causes • Pregnancy/Lactation • Patients with severe hepatic, renal or other systemic disorder • Pre existing malignancy

Design outcomes

Primary

MeasureTime frame
Reduction in VIDA scoringTimepoint: Reduction in VIDA scoring—

Secondary

MeasureTime frame
improvement in VASI, Investigators assessment scores and patients assessment scores, and degree of colour match in repigmentation achieved.Timepoint: fortnightly for 2 months, thereafter, monthly till completion of follow-up.—

Countries

India

Contacts

Public ContactProf Davinder Parsad

PGIMER

parsad@me.com9876060361

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026